Author:
Rodríguez N.E.G.,Aguilera-Alonso D.,Escosa L.,Gómez-Gil M.R.,Manzanares Á.,Ascaso M.G.,Bermejo-Gómez A.,Abad M.J.G.,Ramos A.M.,Núñez A.S.,Orellana M.Á.,Cercenado E.,Lozano J.S.,Calvo C.,Baquero-Artigao F.,Grasa C.,Sánchez Castellano M.,Rodríguez-Molino P.,Castro Martínez M.,de Llano B.B.Q.,San Juan I.
Reference38 articles.
1. An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy;Ciofi;BMC Infect Dis,2014
2. Epidemiology and treatment of multidrug-resistant and extensively drugresistant Pseudomonas aeruginosa infections;Horcajada;Clin Microbiol Rev,2019
3. L.Blatt N. World Health Organization Report: Current crisis of antibiotic resistance;Talebi;BioNanoSci,2019
4. Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2
5. Prevention Epicenters Program, US Centers for Disease Control and Prevention. Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United States, 1999–2012;Logan;J Pediatr Infect Dis Soc,2017